Inflammatory and stress markers predicting pneumonia, outcome, and etiology in patients with stroke: Biomarkers for predicting pneumonia, functional outcome, and death after stroke.


Journal

Neurology(R) neuroimmunology & neuroinflammation
ISSN: 2332-7812
Titre abrégé: Neurol Neuroimmunol Neuroinflamm
Pays: United States
ID NLM: 101636388

Informations de publication

Date de publication:
05 2020
Historique:
received: 15 08 2019
accepted: 27 01 2020
entrez: 27 2 2020
pubmed: 27 2 2020
medline: 3 8 2021
Statut: epublish

Résumé

Prognosis of stroke is negatively affected by complications, in particular stroke-associated pneumonia (SAP). We hypothesized that inflammatory and stress biomarkers predict SAP during hospitalization and outcome 3 months after stroke. We pooled the clinical data of 2 acute stroke studies with identical assessment: the STRoke Adverse outcome is associated WIth NoSoKomial Infections (STRAWINSKI) and PREDICT studies. Measurement of biomarkers (ultrasensitive procalcitonin [PCTus]; midregional pro-adrenomedullin; midregional pro-atrial natriuretic peptide [MRproANP]; ultrasensitive copeptin [CPus]; C-terminal pro-endothelin) was performed from serum samples drawn on the first 4 days of hospital admission. The combined cohort consists of 573 cases with available backup samples to perform the analysis. SAP was associated with increased admission and maximum levels of all biomarkers. Furthermore, all biomarkers were associated with death and correlated with functional outcome 3 months after stroke. The multivariate logistic regression model retained ultrasensitive CPus and PCTus beyond clinical risk factors for predicting SAP, improving the receiver operating characteristic area under the curve (AUC) from 0.837 to 0.876. In contrast, the biomarkers did not improve the prediction of death and functional outcome in the multivariate model. Cardioembolic strokes were significantly associated with higher values of all biomarkers, whereas discrimination was best for MRproANP (AUC = 0.811 for maximum value). The tested biomarkers are associated with SAP and poor functional outcome. However, these biomarkers only slightly improve prediction of SAP and do not improve long-term outcome prediction over clinical parameters. MRproANP showed the best discrimination for identifying cardioembolic stroke, warranting further studies to confirm our finding. clinicaltrials.gov NCT01264549 and NCT01079728.

Identifiants

pubmed: 32098866
pii: 7/3/e692
doi: 10.1212/NXI.0000000000000692
pmc: PMC7051196
pii:
doi:

Banques de données

ClinicalTrials.gov
['NCT01264549', 'NCT01079728']

Types de publication

Clinical Trial Journal Article Multicenter Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Copyright © 2020 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.

Références

Neurology. 2017 May 16;88(20):1899-1905
pubmed: 28424274
PLoS One. 2013 Jul 22;8(7):e68768
pubmed: 23894342
Int J Stroke. 2012 Jul;7(5):435-9
pubmed: 22463131
Stroke. 2015 Aug;46(8):2335-40
pubmed: 26111886
Peptides. 2014 Feb;52:44-8
pubmed: 24333654
Transl Stroke Res. 2019 Sep 2;:
pubmed: 31475302
Front Neurol. 2017 Apr 24;8:153
pubmed: 28484421
Stroke. 2016 Jul;47(7):1714-9
pubmed: 27197849
Front Neurol. 2019 Feb 15;10:83
pubmed: 30828313
Neurocrit Care. 2011 Jun;14(3):416-22
pubmed: 20052623
Peptides. 2014 Feb;52:53-7
pubmed: 24333656
Nat Rev Neurosci. 2005 Oct;6(10):775-86
pubmed: 16163382
Neurology. 2019 Mar 26;92(13):e1517-e1525
pubmed: 30824558
Ann Neurol. 2009 Dec;66(6):799-808
pubmed: 20035506
Hypertens Res. 2017 May;40(5):465-471
pubmed: 27904159
Neuromolecular Med. 2019 Dec;21(4):344-368
pubmed: 30830566
Cerebrovasc Dis. 2012;33(6):580-8
pubmed: 22710977
J Neuroimmunol. 2017 Nov 15;312:19-23
pubmed: 28886956
PLoS One. 2012;7(10):e48309
pubmed: 23118979
Int J Stroke. 2013 Oct;8(7):598-603
pubmed: 22925000
J Cereb Blood Flow Metab. 2017 Dec;37(12):3671-3682
pubmed: 27733675
Eur Stroke J. 2016 Jun;1(2):76-84
pubmed: 31008268
Stroke. 2012 Oct;43(10):2617-23
pubmed: 22798325
Lancet Neurol. 2010 Jan;9(1):105-18
pubmed: 20083041

Auteurs

Benjamin Hotter (B)

From the Charité - Universitätsmedizin Berlin (B.H., S.H., L.U., A.M.), Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health; Center for Stroke Research Berlin, NeuroCure Clinical Research Center and Department of Neurology, Berlin; Friedrich Loeffler Institute of Medical Microbiology (L.U.), University Medicine Greifswald, Greifswald, Germany; Neurovascular Research Laboratory (J.M., A.B.), Vall d'Hebron Institut de Recerca, Barcelona; Stroke Research Program (J.M.), Institute of Biomedicine of Seville, IBiS/Hospital Universitario Virgen del Rocío/CSIC/University of Seville; Department of Neurology (J.M.), Hospital Universitario Virgen Macarena, Spain; and Department of Medical Immunology (C.M.), Charité University Medicine and Labor Berlin - Charité Vivantes GmbH, Berlin, Germany. benjamin.hotter@charite.de.

Sarah Hoffmann (S)

From the Charité - Universitätsmedizin Berlin (B.H., S.H., L.U., A.M.), Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health; Center for Stroke Research Berlin, NeuroCure Clinical Research Center and Department of Neurology, Berlin; Friedrich Loeffler Institute of Medical Microbiology (L.U.), University Medicine Greifswald, Greifswald, Germany; Neurovascular Research Laboratory (J.M., A.B.), Vall d'Hebron Institut de Recerca, Barcelona; Stroke Research Program (J.M.), Institute of Biomedicine of Seville, IBiS/Hospital Universitario Virgen del Rocío/CSIC/University of Seville; Department of Neurology (J.M.), Hospital Universitario Virgen Macarena, Spain; and Department of Medical Immunology (C.M.), Charité University Medicine and Labor Berlin - Charité Vivantes GmbH, Berlin, Germany.

Lena Ulm (L)

From the Charité - Universitätsmedizin Berlin (B.H., S.H., L.U., A.M.), Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health; Center for Stroke Research Berlin, NeuroCure Clinical Research Center and Department of Neurology, Berlin; Friedrich Loeffler Institute of Medical Microbiology (L.U.), University Medicine Greifswald, Greifswald, Germany; Neurovascular Research Laboratory (J.M., A.B.), Vall d'Hebron Institut de Recerca, Barcelona; Stroke Research Program (J.M.), Institute of Biomedicine of Seville, IBiS/Hospital Universitario Virgen del Rocío/CSIC/University of Seville; Department of Neurology (J.M.), Hospital Universitario Virgen Macarena, Spain; and Department of Medical Immunology (C.M.), Charité University Medicine and Labor Berlin - Charité Vivantes GmbH, Berlin, Germany.

Joan Montaner (J)

From the Charité - Universitätsmedizin Berlin (B.H., S.H., L.U., A.M.), Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health; Center for Stroke Research Berlin, NeuroCure Clinical Research Center and Department of Neurology, Berlin; Friedrich Loeffler Institute of Medical Microbiology (L.U.), University Medicine Greifswald, Greifswald, Germany; Neurovascular Research Laboratory (J.M., A.B.), Vall d'Hebron Institut de Recerca, Barcelona; Stroke Research Program (J.M.), Institute of Biomedicine of Seville, IBiS/Hospital Universitario Virgen del Rocío/CSIC/University of Seville; Department of Neurology (J.M.), Hospital Universitario Virgen Macarena, Spain; and Department of Medical Immunology (C.M.), Charité University Medicine and Labor Berlin - Charité Vivantes GmbH, Berlin, Germany.

Alejandro Bustamante (A)

From the Charité - Universitätsmedizin Berlin (B.H., S.H., L.U., A.M.), Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health; Center for Stroke Research Berlin, NeuroCure Clinical Research Center and Department of Neurology, Berlin; Friedrich Loeffler Institute of Medical Microbiology (L.U.), University Medicine Greifswald, Greifswald, Germany; Neurovascular Research Laboratory (J.M., A.B.), Vall d'Hebron Institut de Recerca, Barcelona; Stroke Research Program (J.M.), Institute of Biomedicine of Seville, IBiS/Hospital Universitario Virgen del Rocío/CSIC/University of Seville; Department of Neurology (J.M.), Hospital Universitario Virgen Macarena, Spain; and Department of Medical Immunology (C.M.), Charité University Medicine and Labor Berlin - Charité Vivantes GmbH, Berlin, Germany.

Christian Meisel (C)

From the Charité - Universitätsmedizin Berlin (B.H., S.H., L.U., A.M.), Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health; Center for Stroke Research Berlin, NeuroCure Clinical Research Center and Department of Neurology, Berlin; Friedrich Loeffler Institute of Medical Microbiology (L.U.), University Medicine Greifswald, Greifswald, Germany; Neurovascular Research Laboratory (J.M., A.B.), Vall d'Hebron Institut de Recerca, Barcelona; Stroke Research Program (J.M.), Institute of Biomedicine of Seville, IBiS/Hospital Universitario Virgen del Rocío/CSIC/University of Seville; Department of Neurology (J.M.), Hospital Universitario Virgen Macarena, Spain; and Department of Medical Immunology (C.M.), Charité University Medicine and Labor Berlin - Charité Vivantes GmbH, Berlin, Germany.

Andreas Meisel (A)

From the Charité - Universitätsmedizin Berlin (B.H., S.H., L.U., A.M.), Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health; Center for Stroke Research Berlin, NeuroCure Clinical Research Center and Department of Neurology, Berlin; Friedrich Loeffler Institute of Medical Microbiology (L.U.), University Medicine Greifswald, Greifswald, Germany; Neurovascular Research Laboratory (J.M., A.B.), Vall d'Hebron Institut de Recerca, Barcelona; Stroke Research Program (J.M.), Institute of Biomedicine of Seville, IBiS/Hospital Universitario Virgen del Rocío/CSIC/University of Seville; Department of Neurology (J.M.), Hospital Universitario Virgen Macarena, Spain; and Department of Medical Immunology (C.M.), Charité University Medicine and Labor Berlin - Charité Vivantes GmbH, Berlin, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH